Literature DB >> 32747809

Rational discovery of molecular glue degraders via scalable chemical profiling.

Sophie Bauer1, Matthias Brand1, Cristina Mayor-Ruiz1, Zuzanna Kozicka2,3, Marton Siklos1, Hana Imrichova1, Ines H Kaltheuner4, Elisa Hahn1, Kristina Seiler1, Anna Koren1, Georg Petzold2, Michaela Fellner5, Christoph Bock1,6, André C Müller1, Johannes Zuber5, Matthias Geyer4, Nicolas H Thomä2, Stefan Kubicek1, Georg E Winter7.   

Abstract

Targeted protein degradation is a new therapeutic modality based on drugs that destabilize proteins by inducing their proximity to E3 ubiquitin ligases. Of particular interest are molecular glues that can degrade otherwise unligandable proteins by orchestrating direct interactions between target and ligase. However, their discovery has so far been serendipitous, thus hampering broad translational efforts. Here, we describe a scalable strategy toward glue degrader discovery that is based on chemical screening in hyponeddylated cells coupled to a multi-omics target deconvolution campaign. This approach led us to identify compounds that induce ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. Notably, this interaction is independent of a dedicated substrate receptor, thus functionally segregating this mechanism from all described degraders. Collectively, our data outline a versatile and broadly applicable strategy to identify degraders with nonobvious mechanisms and thus empower future drug discovery efforts.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32747809      PMCID: PMC7116640          DOI: 10.1038/s41589-020-0594-x

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  45 in total

Review 1.  Small-Molecule PROTACS: New Approaches to Protein Degradation.

Authors:  Momar Toure; Craig M Crews
Journal:  Angew Chem Int Ed Engl       Date:  2016-01-12       Impact factor: 15.336

2.  Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.

Authors:  K M Sakamoto; K B Kim; A Kumagai; F Mercurio; C M Crews; R J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Authors:  Georg E Winter; Dennis L Buckley; Joshiawa Paulk; Justin M Roberts; Amanda Souza; Sirano Dhe-Paganon; James E Bradner
Journal:  Science       Date:  2015-05-21       Impact factor: 47.728

4.  Catalytic in vivo protein knockdown by small-molecule PROTACs.

Authors:  Daniel P Bondeson; Alina Mares; Ian E D Smith; Eunhwa Ko; Sebastien Campos; Afjal H Miah; Katie E Mulholland; Natasha Routly; Dennis L Buckley; Jeffrey L Gustafson; Nico Zinn; Paola Grandi; Satoko Shimamura; Giovanna Bergamini; Maria Faelth-Savitski; Marcus Bantscheff; Carly Cox; Deborah A Gordon; Ryan R Willard; John J Flanagan; Linda N Casillas; Bartholomew J Votta; Willem den Besten; Kristoffer Famm; Laurens Kruidenier; Paul S Carter; John D Harling; Ian Churcher; Craig M Crews
Journal:  Nat Chem Biol       Date:  2015-06-10       Impact factor: 15.040

5.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

6.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

7.  Chemical genetic control of protein levels: selective in vivo targeted degradation.

Authors:  John S Schneekloth; Fabiana N Fonseca; Michael Koldobskiy; Amit Mandal; Raymond Deshaies; Kathleen Sakamoto; Craig M Crews
Journal:  J Am Chem Soc       Date:  2004-03-31       Impact factor: 15.419

8.  Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.

Authors:  Michael Zengerle; Kwok-Ho Chan; Alessio Ciulli
Journal:  ACS Chem Biol       Date:  2015-06-16       Impact factor: 5.100

9.  Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.

Authors:  Quinlan L Sievers; Georg Petzold; Richard D Bunker; Aline Renneville; Mikołaj Słabicki; Brian J Liddicoat; Wassim Abdulrahman; Tarjei Mikkelsen; Benjamin L Ebert; Nicolas H Thomä
Journal:  Science       Date:  2018-11-02       Impact factor: 47.728

10.  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

Authors:  Anita K Gandhi; Jian Kang; Courtney G Havens; Thomas Conklin; Yuhong Ning; Lei Wu; Takumi Ito; Hideki Ando; Michelle F Waldman; Anjan Thakurta; Anke Klippel; Hiroshi Handa; Thomas O Daniel; Peter H Schafer; Rajesh Chopra
Journal:  Br J Haematol       Date:  2013-12-13       Impact factor: 6.998

View more
  33 in total

Review 1.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

2.  Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.

Authors:  Rati Verma
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras.

Authors:  He Chen; Jing Liu; H Ümit Kaniskan; Wenyi Wei; Jian Jin
Journal:  J Med Chem       Date:  2021-08-11       Impact factor: 8.039

4.  Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.

Authors:  Lu Lv; Peihao Chen; Longzhi Cao; Yamei Li; Zhi Zeng; Yue Cui; Qingcui Wu; Jiaojiao Li; Jian-Hua Wang; Meng-Qiu Dong; Xiangbing Qi; Ting Han
Journal:  Elife       Date:  2020-08-17       Impact factor: 8.140

Review 5.  Ubiquitin-dependent regulation of transcription in development and disease.

Authors:  Kevin G Mark; Michael Rape
Journal:  EMBO Rep       Date:  2021-03-28       Impact factor: 8.807

Review 6.  Decoding the messaging of the ubiquitin system using chemical and protein probes.

Authors:  Lukas T Henneberg; Brenda A Schulman
Journal:  Cell Chem Biol       Date:  2021-04-07       Impact factor: 8.116

Review 7.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

Review 8.  Cell cycle on the crossroad of tumorigenesis and cancer therapy.

Authors:  Jing Liu; Yunhua Peng; Wenyi Wei
Journal:  Trends Cell Biol       Date:  2021-07-22       Impact factor: 20.808

Review 9.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

Review 10.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.